Financials in GBp. Standardized financial statements.
A compact view of how Argent BioPharma Limited turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | £891,083 | £3.39M | £4.73M | £2.96M | £1.16M | £362,787 | £166,445 | £70,948 | £1,231 | £0 |
| Revenue Growth? | -73.7% | -28.4% | +59.7% | +155.9% | +219.2% | +118.0% | +134.6% | +5663.4% | 0.0% | 0.0% |
| Cost of Revenue? | £687,386 | £1.94M | £2.92M | £1.65M | £1.06M | £197,162 | £66,923 | £93,270 | £8,411 | £0 |
| Gross Profit? | £203,697 | £1.45M | £1.81M | £1.31M | £97,283 | £165,625 | £99,522 | -£22,322 | -£7,180 | £0 |
| Gross Margin? | +22.9% | +42.8% | +38.3% | +44.2% | +8.4% | +45.7% | +59.8% | -31.5% | -583.3% | 0.0% |
| Operating Expenses? | £203,697 | £1.45M | £1.81M | £1.31M | £10.49M | £6.38M | £3.54M | £3.91M | £1.27M | £390,298 |
| Operating Income? | -£16.70M | -£15.60M | -£14.26M | -£12.07M | -£10.39M | -£6.21M | -£3.44M | -£3.93M | -£1.28M | -£390,000 |
| EBITDA? | -£15.77M | -£20.12M | -£20.31M | -£14.58M | -£6.11M | -£4.67M | -£3.77M | -£4.13M | -£1.37M | -£418,000 |
| Income Before Tax | -£17.55M | -£21.13M | -£20.77M | -£15.44M | -£10.45M | -£6.10M | -£5.04M | -£5.02M | -£3.49M | -£1.86M |
| Income Tax Expense | £0 | £2,018 | £0 | -£27,278 | £0 | £15,100 | £0 | £0 | £0 | £0 |
| Net Income? | -£17.53M | -£20.82M | -£20.35M | -£15.87M | -£10.79M | -£4.74M | -£4.62M | -£4.81M | -£3.45M | -£1.86M |
| EPS? | £-0.47 | £-7.11 | £-7.63 | £-7.01 | £-7.34 | £-6.46 | £-4.11 | £-4.97 | £-5.72 | £-6.57 |
| Diluted EPS? | £-0.47 | £-7.07 | £-7.63 | £-6.95 | £-7.56 | £-5.03 | £-4.11 | £-4.97 | £-5.72 | £-6.57 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality